Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
MTCR - Metacrine Inc
$9.00
0.08(0.90%)9:00:01 PM 1/15/2021
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases in the United States. It is developing MET409, a therapy that is in a Phase Ib proof-of-concept clinical trial for the treatment of non-alcoholic steatohepatitis patients; and MET642, a candidate, which is in Phase 1 clinical trial for the treatment of non-alcoholic steatohepatitis patients. The company has a research collaboration with Novo Nordisk A/S to perform research activities related to fibroblast growth factor 1. Metacrine, Inc. was founded in 2014 and is headquartered in San Diego, California.
Stock Chart

Summary:

  • MACD is crossing MACD signal line at 0.1. MACD crossing signal line is bullish signal.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics

Stock news

    01/5/2021MTCR
    Metacrine Initiates Phase 2a Combination Trial of MET409 with Empagliflozin in Patients with Type 2 Diabetes and NASH

    Trial Designed to Evaluate Potential of FXR-Based Combination Therapy in a Growing Segment of NASH Patient Population with Significant Unmet NeedsSAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that the first patient has been treated in the company’s Phase 2a trial evaluating MET409 (50 mg) in...

    12/17/2020MTCR
    Metacrine Reports Positive Results from Phase 1 Trial of MET642

    MET642 Demonstrated Sustained Pharmacokinetic Profile and Robust FXR Target Engagement with Once-Daily Oral Dosing, without Pruritis or LDL-Cholesterol Increase Doses Selected for Phase 2a Trial in Patients with NASH; On-Track to Initiate in 1H21SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today reported ...

    12/16/2020MTCR
    What Percentage Of Metacrine, Inc. (NASDAQ:MTCR) Shares Do Insiders Own?

    A look at the shareholders of Metacrine, Inc. ( NASDAQ:MTCR ) can tell us which group is most powerful. Insiders often...

    12/8/2020MTCR
    Is MTCR A Good Stock To Buy Now?

    In this article you are going to find out whether hedge funds think Metacrine, Inc. (NASDAQ:MTCR) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among […]

    11/23/2020MTCR
    Metacrine to Participate in Upcoming Investor Conferences

    SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine, will present at the following December investor conferences: * Piper Sandler 32nd Annual Virtual Healthcare Conference (fireside chat) being held December 1-3...

    11/12/2020MTCR
    Metacrine Reports Business Updates and Third Quarter 2020 Financial Results

    Upcoming Data at AASLD Support Robust, Sustained FXR Activation by MET409 in Patients with NASH $85 Million Initial Public Offering Completed SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today reported recent business highlights and third quarter 2020 financial results.“2020 has been a transformational ye...

    10/3/2020MTCR
    Metacrine, Prelude Therapeutics See Activist Action

    New Enterprise Associates revealed a large investment in biopharmaceutical company Metacrine. Baker Brothers Advisors disclosed an initial position in oncology-focused biopharmaceutical firm of Prelude.

    10/1/2020MTCR
    Metacrine to Present New Data from MET409 Program in NASH at AASLD’s The Liver Meeting Digital Experience™

    New Data Support Robust, Sustained FXR Activation by MET409 in Patients with NASH and Demonstrate Predictability of Liver Fat Reductions as Early as Week 4 of TreatmentSAN DIEGO, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that two posters highlighting new data on the company’s lead clinical candidat...